1. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015; 348(6230): 69-74. doi: 10.1126/science.aaa4971
2. Srivastava PK. Neoepitopes of cancers: looking back, looking ahead. Cancer Immunol Res. 2015; 3(9): 969-977. doi: 10.1158/2326-6066
3. Yuan J, Hegde PS, Clynes R, et al. Novel technologies and emerging biomarkers for personalized cancer immunotherapy. J Immunother Cancer. 2016; 4: 3. doi: 10.1186/s40425-016-0107-3
4. Ma W, Gilligan, BM, Yuan J, Li T. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016; 9(1): 47. doi: 10.1186/s13045-016-0277-y
5. Leko V, McDuffie LA, Zheng Z, et al. Identification of neoantigen reactive tumor infiltrating lymphocytes in primarybladder cancer. J Immunol. 2019; 202(12): 3458-3467. doi: 10.4049/jimmunol.1801022
6. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594): 850-854. doi: 10.1126/science.1076514
7. Dudley ME, Yang JC, Sherry R, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008; 26(32): 5233-5239. doi: 10.1200/JCO.2008
8. van Roji N, van Burren MM, Philips D, et al. Tumor exome analysis reveals neoantigen specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol. 2013; 31(32): e439-e442. doi: 10.1200/JCO.2012.47.7521
9. Linnemann C, van Burren MM, Bies L, et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med. 2015; 21(1): 81-85. doi: 10.1038/nm.3773
10. Lu YC, Yao X, Crystal JS, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014; 20(13): 3401-3410. doi: 10.1158/1078-0432
11. Rahma OE, Hamilton JM, Wojtowicz M, et al. The immunological and clinical effects of mutated Ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014; 12:55. doi: 10.1186/1479-5876-12-55
12. Chheda ZS, Kohanbash G, Okada K, et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med. 2018; 215(1): 141-157. doi: 10.1084/jem.20171046
13. Deniger DC, Pasetto A, Robbins PF, et al. T-cell responses to TP53 “hotspot” mutations and unique neoantigens expressed by human ovarian cancers. Clin Cancer Res. 2018; 24(22): 5562-5573. doi: 10.1158/1078-0432
14. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547(7662): 217-221. doi: 10.1038/nature22991